Lilly Presents New Data on Dermatology Treatments

Eli Lilly and Company is set to present 21 abstracts at the Fall Clinical 2026 conference, focusing on advancements in its dermatology portfolio. The presentations aim to further the understanding and treatment of chronic skin conditions.

Key among the presentations are new data for EBGLYSS (lebrikizumab-lbkz), a treatment for moderate-to-severe atopic dermatitis. These findings reinforce the drug's ability to provide durable disease control, allow for less frequent maintenance dosing, and reduce the need for topical treatments.

The company will also share exploratory biomarker analyses. These studies are designed to offer deeper insights into the immunometabolic biology of atopic dermatitis, potentially identifying new therapeutic targets or strategies.

Lilly's participation in the event underscores its commitment to addressing unmet needs in dermatology. The presented data are expected to contribute to the evolving landscape of chronic skin condition management.